RNA-Binding Protein HuR Emerges as a Master Switch in Tau Splicing and Alzheimer’s Genes

Deep inside every neuron, a molecular editing decision is made thousands of times per second: which pieces of a gene’s message are kept and which are discarded. For the tau protein, that decision can be a matter of brain health or brain disease. A new study published in Molecular Genetics and Genomics has identified a key player in this process, showing that the RNA-binding protein HuR acts as a repressor of alternative splicing at the MAPT gene, the gene that encodes tau. Because imbalanced production of tau isoforms is a hallmark of Alzheimer’s disease and related tauopathies, the finding offers researchers a fresh molecular handle on one of the most stubborn problems in neurodegeneration.

The story begins with exon 10 of the MAPT gene. Tau exists in the human brain as six isoforms, distinguished by whether they contain three or four microtubule-binding repeats, the so-called 3R and 4R forms. The inclusion or skipping of exon 10 determines which repeat is present, and the normal adult brain maintains a roughly balanced ratio of the two. When that ratio slips, the consequences can be devastating: mutations and splicing dysregulation around exon 10 are linked to a family of disorders including progressive supranuclear palsy, corticobasal degeneration, Pick’s disease, and frontotemporal dementia with parkinsonism linked to chromosome 17, as well as Alzheimer’s disease itself, where neurofibrillary tangles of tau accumulate inside dying neurons.

Scientists have known for years that exon 10 is governed by an intricate web of cis-acting sequence elements and trans-acting proteins. Previous work had implicated factors such as TDP-43, hnRNP A1, Rbfox3, and hnRNP C in controlling this splicing decision. The new study, led by Yaqiong Yu and colleagues with senior authors Tao Jiang and Deng Xiao, adds HuR, also known as ELAVL1, to that roster, and does so with a mechanistic depth that distinguishes it from a simple correlation. Using a combination of reporter assays, binding studies, and transcriptome-wide analyses, the team demonstrated that HuR does not merely associate with the MAPT pre-messenger RNA; it actively suppresses the inclusion of exon 10.

The mechanistic core of the finding lies in a specific structural domain of the HuR protein. HuR belongs to the embryonic lethal abnormal vision family of RNA-binding proteins and carries three RNA recognition motifs, or RRMs. Through systematic domain analysis, the researchers showed that the first of these motifs, RRM1, is critical for HuR’s splicing-inhibitory effect on exon 10. When this domain’s function was disrupted, the repressive effect was lost. This level of resolution matters because it converts a broad observation, that HuR touches tau RNA, into a testable molecular model in which a defined protein surface contacts a defined RNA target to alter a splicing outcome relevant to human disease.

Where exactly does HuR bind? The answer, according to the study, is a uridine-rich stretch of sequence located downstream of intron 9 in the MAPT pre-mRNA, immediately adjacent to the exon 10 region whose inclusion it represses. U-rich elements are a classic signature of ELAV-family protein binding, and genome-wide surveys have previously revealed that a large proportion of AU-rich elements across the human transcriptome sit within introns, where they can influence splicing as well as mRNA stability. The intronic location of the HuR binding site in MAPT fits this pattern neatly and provides a plausible physical mechanism: by occupying the downstream intron, HuR may interfere with the spliceosome’s recognition of the exon, tipping the balance toward skipping.

Perhaps the most intriguing aspect of the study is its demonstration that HuR does not work alone. The researchers found that HuR binds the U-rich region in MAPT together with a cohort of cooperating RNA-binding proteins: FUBP1, KHSRP, hnRNPD, hnRNPAB, hnRNPDL, and TIAL1. Splicing decisions in mammalian cells are rarely made by a single factor; instead, regulatory complexes assemble cooperatively on pre-mRNA, and the combined occupancy of activators and repressors determines the final output. The identification of this multi-protein assembly at the tau exon 10 locus suggests that the ratio of 3R to 4R tau is set by a network rather than a switch, with HuR functioning as one node whose influence depends on its partners.

Adding another layer of complexity, the team observed that HuR expression shows a negative relationship with the expression of several of these partners, including FUBP1, KHSRP, hnRNPD, and TIAL1. Such inverse expression patterns hint at cross-regulatory circuits among RNA-binding proteins, a phenomenon documented before in the hnRNP family, where auto- and cross-regulation help maintain proteostasis of the splicing machinery. If HuR and its co-factors restrain one another’s abundance, then perturbations that shift one factor, whether through aging, stress signaling, or disease processes, could ripple through the entire complex and reshape tau splicing in neurons. This systems-level view reframes tauopathies not as failures of a single gene but as failures of a regulatory network.

The implications extend well beyond MAPT. When the researchers examined the broader consequences of altering HuR levels, they found that the protein regulates both the expression and the alternative splicing of genes involved in autophagy and apoptosis, the cellular self-cleaning and self-destruction pathways that are famously dysregulated in Alzheimer’s disease. Defective autophagy is thought to contribute to the accumulation of amyloid-beta and phosphorylated tau, while inappropriate apoptosis drives neuronal loss. The idea that a single RNA-binding protein sits upstream of splicing programs in both pathways positions HuR as a potential coordinator of several AD-relevant transcriptomic networks simultaneously, a convergence point where multiple disease processes might intersect.

This broader role is consistent with a growing literature on the ELAV family in the nervous system. HuR has been shown to control the RNA metabolism of glutaminase, to regulate age-related hearing loss in mice, and to interact with amyloid precursor protein in ways that promote apoptosis under amyloid-beta stress. Its cousin ELAVL4 has been implicated in splicing changes and glutamatergic dysfunction that precede neuron loss in cerebral organoids carrying MAPT mutations, and ELAVL2-family biology has been linked to neuroprotection in retinal ganglion cells. The new study slots neatly into this picture while adding something genuinely new: a direct, mechanistically resolved connection between HuR and the splicing event most tightly associated with tauopathy.

Therapeutically, the timing is notable. Antisense oligonucleotides targeting tau are already in clinical trials, with a phase 1b study of the MAPT-targeting agent MAPTRx in mild Alzheimer’s disease demonstrating that tau-directed RNA therapies can reach the nervous system safely. A splicing-factor approach would represent a different strategy: rather than reducing total tau, it would aim to restore the correct 3R-to-4R ratio by modulating the proteins that decide exon 10’s fate. The identification of RRM1 as the critical functional domain of HuR provides a concrete target for such efforts, whether through small molecules that disrupt the HuR-RNA interaction or through oligonucleotides that mask the U-rich binding site in intron 9. Similar splicing-correction approaches have already rescued mis-splicing in other genetic diseases, including sensorineural hearing loss and spinal muscular atrophy, proving the concept is feasible.

Caution is warranted, as it always is in this field. HuR is a multifunctional protein with hundreds of documented RNA targets, and global manipulation of its activity could produce unintended effects in cells throughout the body. The negative correlations between HuR and its co-factor expression, while suggestive, raise questions about cause and effect that will require longitudinal and cell-type-specific studies to resolve. Moreover, the study was conducted without human participants or animal subjects, so translating these molecular findings into living brains remains a substantial journey. Even so, the work delivers something Alzheimer’s research badly needs: a new, mechanistically grounded entry point into the splicing decisions that shape tau biology, and a reminder that the answers to neurodegeneration may lie not only in the proteins that misfold, but in the RNA editors that decide which versions of those proteins are made in the first place.

Subject of Research: The role of the RNA-binding protein HuR in regulating alternative splicing of MAPT and other Alzheimer's disease-related genes

Article Title: HuR modulates disease-relevant alternative splicing of MAPT and other Alzheimer's disease-related genes

Article References: HuR modulates disease-relevant alternative splicing of MAPT and other Alzheimer's disease-related genes. (n.d.). https://doi.org/10.1007/s00438-026-02527-8

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02527-8

Keywords: HuR, ELAVL1, MAPT, tau, alternative splicing, Alzheimer's disease, tauopathies, exon 10, RNA-binding proteins, autophagy, apoptosis, neurodegeneration